Valuation: Control Bionics Limited

Market Cap 30.49M 21.52M 18.65M 17.46M 15.93M 29.98M 2.05B 205M 80.22M 1.03B 80.81M 79.05M 3.43B P/E 2024
-1.4x
P/E 2025 -1.3x
Enterprise Value 30.25M 21.36M 18.51M 17.33M 15.81M 29.75M 2.04B 203M 79.59M 1.02B 80.18M 78.44M 3.4B EV / Sales 2024
1.92x
EV / Sales 2025 1.4x
Free-Float
55.4%
Yield 2024 *
-
Yield 2025 -
1 day-7.46%
1 week-4.62%
Current month-3.12%
1 month-15.07%
3 months-8.82%
6 months+10.71%
Current year+1.64%
1 week 0.06
Extreme 0.062
0.07
1 month 0.06
Extreme 0.061
0.08
Current year 0.05
Extreme 0.05
0.1
1 year 0.03
Extreme 0.032
0.1
3 years 0.03
Extreme 0.026
0.1
5 years 0.03
Extreme 0.026
0.74
10 years 0.03
Extreme 0.026
1.24
Manager TitleAgeSince
Chief Executive Officer - 18/01/2023
Director of Finance/CFO - 12/05/2024
Chief Tech/Sci/R&D Officer - 31/12/2013
Director TitleAgeSince
Chairman 66 18/11/2025
Director/Board Member - 18/01/2023
Director/Board Member - 31/03/2023
Change 5-day change 1-year change 3-year change Capi.($)
-7.46%-4.62%+40.91%-24.85% 21.08M
-0.13%+4.70%+29.83%-33.88% 17.28B
+5.67%-5.02%-6.81%+102.62% 1.66B
+0.29%+2.05%-26.95%+24.46% 1B
+2.51%-19.51%-40.14%-81.84% 943M
+0.65%+50.24%+90.23%-10.82% 778M
-0.79%+1.52%-37.18%-51.37% 682M
+5.71%+10.00%-43.74%-46.29% 563M
+0.75%+5.46%-44.70%-43.57% 412M
+1.57%+4.03%-6.30%-21.42% 383M
Average +0.82%+44.75%-4.49%-18.70% 2.37B
Weighted average by Cap. +0.38%+172.86%+18.52%-23.76%

Financials

2024 2025
Net sales 5.35M 3.78M 3.27M 3.06M 2.8M 5.26M 360M 35.94M 14.08M 180M 14.18M 13.88M 602M 6.14M 4.34M 3.76M 3.52M 3.21M 6.04M 414M 41.27M 16.17M 207M 16.29M 15.93M 691M
Net income -5.91M -4.18M -3.62M -3.39M -3.09M -5.82M -398M -39.72M -15.56M -199M -15.68M -15.34M -665M -6.11M -4.31M -3.74M -3.5M -3.19M -6.01M -411M -41.03M -16.07M -206M -16.19M -15.84M -687M
Net Debt -96.95K -68.45K -59.31K -55.53K -50.67K -95.34K -6.53M -651K -255K -3.27M -257K -251K -10.9M -237K -168K -145K -136K -124K -233K -15.98M -1.59M -624K -8M -629K -615K -26.68M
Logo Control Bionics Limited
Control Bionics Limited is a medical device company assisting patients whose ability to communicate verbally or via text and social media is compromised by illnesses, such as Motor Neurone Disease and Amyotrophic Lateral Sclerosis. Its products include Control Bionics Trilogy Systems, NeuroStrip, NeuroNode, Cosmos Connect and accessories. NeuroNode technology is a wireless wearable device that detects minute signals sent from the brain to any skeletal muscle and is captured as electromyography output. This output is then sent wirelessly via NeuroNode to a personal computer, enabling speech and other computer-controlled functions like email and texting. Its technology is integrated with eye gaze technology whereby the eye gaze enables a cursor to be moved about a computer screen, driven much like a mouse and the NeuroNode acts like a mouse button. It is commercializing its advancement in its technology, NeuroStrip. It is focused on neuromuscular rehabilitation and athletic optimization.
Employees
-
Date Price Change Volume
11/08/26 A$0.0620 -7.46% 548,731
10/08/26 A$0.0670 -2.90% 199,658
07/08/26 A$0.0690 0.00% 8,000
06/08/26 A$0.0690 -1.43% 81,214
05/08/26 A$0.0700 +9.38% 359,991

Annual profits - Rate of surprise